International Society for Pharmacoeconomics and Outcomes Research

Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety

Retrieved on: 
Friday, September 30, 2022
Hospital, Safety, Therapy, IPF, Probability, Incidence, MAP, COVID-19, MAPK, DSMB, Severe acute respiratory syndrome coronavirus 2, Knowledge, Idiopathic pulmonary fibrosis, Patient, Disease, CEO, United States Medical Licensing Examination, Cell, Idiopathic disease, Drug development, Data monitoring committee, AMD, KNRS, Pioglitazone, International Society for Pharmacoeconomics and Outcomes Research, Pharmaceutical industry, Muthiri kinaru

Safety data from KINETIC study indicate a favorable profile, with a balanced incidence of treatment-emergent adverse events (TEAEs) between study groups.

Key Points: 
  • Safety data from KINETIC study indicate a favorable profile, with a balanced incidence of treatment-emergent adverse events (TEAEs) between study groups.
  • While it is disappointing that KIN001 has not shown sufficient signs of efficacy in the KINETIC study, it is important to remember that hospitalized COVID-19 patients have severe disease with highly complicated pathophysiology.
  • For these reasons, we are continuing to study KIN001 as planned in KINFAST, a second Phase 2 study in ambulatory COVID-19 patients who are not hospitalized remarked Dr Fumeaux.
  • Kinarus Therapeutics plans to study the potential of KIN001 as a treatment for wet Age-Related Macular Degeneration and Idiopathic Pulmonary Fibrosis.

Real World Evidence Solutions Global Market Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 20, 2022
Biotechnology, Medical Devices, Seniors, Consumer, Health, Real-World Evidence, Pharmacoeconomics, Degenerative disease, RWE, Culture, National Accreditation Board for Hospitals & Healthcare Providers, Risk, Arthritis, Real, Growth, Stroke, Drug development, Cancer, Type 2 diabetes, Solution, International Society, International Society for Pharmacoeconomics and Outcomes Research, Research, Ageing, Orthostatic hypotension, Conditional sentence, Medical device

The "Real World Evidence Solutions Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Real World Evidence Solutions Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • North America was the largest region in the real world evidence solutions market in 2021.
  • The regions covered in the real-world evidence solutions market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
  • The development of real-world evidence has become a key trend, gaining popularity in the real-world evidence market.

VBI Vaccines Presented Health Economics and Outcomes Research for PreHevbrio™ at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022

Retrieved on: 
Thursday, May 19, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Disease, HBV, VLP, Infection, Cirrhosis, Liver cancer, Allergy, Virus, VBI, Poster, Private Securities Litigation Reform Act, Headache, Immune system, SEC, Fatigue, Annual report, Anaphylaxis, Pharmacoeconomics, CMV, International Society, Pain, Woman, Outcomes research, Nature, European, COVID-19, Research, Immunodeficiency, GBM, Company, Hepatitis B, Health Economics, Myalgia, New Resource Bank, International Society for Pharmacoeconomics and Outcomes Research, VAERS, Hepatocellular carcinoma, Pregnancy, Hepatitis B virus, Tenderness, History, Nasdaq, Patient, EU, Cytomegalovirus, Vaccine, Industry, Liver disease, Glioblastoma, Person, News, Medicine, Birth control

Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.

Key Points: 
  • Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.
  • An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

OncoHealth™ Unveils Real-World Evidence Dashboard for Pan Tumor, Immunotherapy Research

Retrieved on: 
Monday, May 16, 2022
Pharmacoeconomics, International Society, Immunotherapy, Overalls, Multimedia, Patient, View, International Society for Pharmacoeconomics and Outcomes Research, FDA, Gaylord National Resort & Convention Center, HIPAA, Growth, Cancer, Diagnosis, List of life sciences, Medical imaging, Pharmaceutical industry, Online shopping, D.C

ATLANTA, May 16, 2022 /PRNewswire/ -- OncoHealth, the leading digital health company dedicated to oncology, unveiled, today, a new real-world evidence dashboard that enables researchers to study the comparative effectiveness and market performance of immunotherapies. Powered by clinically rich, real-time, pan tumor immunotherapy data and combined with advanced analytics, DashIO™ provides researchers with the ability to query and visualize low-latency real-world data on immune checkpoint inhibitors.

Key Points: 
  • Powered by clinically rich, real-time, pan tumor immunotherapy data and combined with advanced analytics, DashIO provides researchers with the ability to query and visualize low-latency real-world data on immune checkpoint inhibitors.
  • "Immune checkpoint inhibitors are among the most promising and the fastest-growing drug class in oncology.
  • This rapid growth has created a "wild west" of immunotherapy that has proven difficult for life sciences companies to track in both a timely and comprehensive manner," said Steve Davis, President of Life Science at OncoHealth.
  • Supporting more than 8 million people in the US and Puerto Rico, OncoHealth offers digital solutions for treatment review, real-world evidence, and telehealth across all cancer types.

Pathnostics to Present New Real-World Method to Identify and Evaluate Cost Outcomes of a Novel, Uncoded UTI Diagnostic at the International Society for Pharmacoeconomics and Outcomes Research 2022 Annual Meeting

Retrieved on: 
Monday, May 16, 2022
Pharmacoeconomics, Risk, International Society, Urinary tract infection, Nasdaq-100, National Harbor, Maryland, Cutis, Infection, Multimedia, Patient, Poster, View, Solution, Microbiology, Health, Nature Reviews Microbiology, UTI, Health care, Epidemiology, Medicare, International Society for Pharmacoeconomics and Outcomes Research, Conference, PCR, SUC, Therapy, MRU, Medical imaging, MD

IRVINE, Calif., May 16, 2022 /PRNewswire/ -- Pathnostics, a leading precision diagnostic testing and development company, today announced that it will present a new Medicare-claims-based method to identify an uncoded novel diagnostic (NDx), Guidance® UTI, and an analysis that found significantly lower costs as compared to standard urine culture (SUC) in patients with complicated urinary tract infections (cUTIs). The methodology and key findings will be presented at the 2022 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting, taking place from May 15-18, in National Harbor, MD.

Key Points: 
  • The methodology and key findings will be presented at the 2022 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting, taking place from May 15-18, in National Harbor, MD.
  • Complicated urinary tract infections, which must be treated early and accurately to reduce the risk of poor outcomes, are a significant burden on individual health and healthcare resources.
  • Annually, UTIs contribute to 10.5 million office visits and carry a cost of approximately $3.5 billioni.
  • Details of the poster presentation are as follows:
    The abstract and poster are now available on the ISPOR 2022 Conference website.

Ontada Research Highlights Power of Real-World Oncology Data at ISPOR 2022

Retrieved on: 
Friday, May 13, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, 2021 Essex County Council election, Pharmacoeconomics, International Society for Pharmacoeconomics and Outcomes Research, Drug development, Education, Electronic health record, EHR, Solution, Clinical trial, International Society, Exclusion, McKesson Corporation, Technology, Medical imaging

Ontada , a McKesson business focused on provider technology and actionable real-world research, education and evidence in oncology, announced the acceptance of seven abstracts for presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Key Points: 
  • Ontada , a McKesson business focused on provider technology and actionable real-world research, education and evidence in oncology, announced the acceptance of seven abstracts for presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
  • The leading global conference for health economics and outcomes research, ISPOR 2022 will take place in Washington, D.C., and virtually from May 15-18, 2022.
  • The acceptance of these studies showcases the critical role Ontadas real-world data and evidence solutions play in our life science partners ability to accelerate the development and commercialization of oncology therapies, said Susan Shiff, Ph.D., president of Ontada.
  • Ontadas data scientists and researchers leveraged our real-world data and analytics capabilities in additional poster studies to be presented at this years ISPOR:

CorEvitas, LLC and Inovalon Highlight Data Linkage Efficiencies at ISPOR

Retrieved on: 
Thursday, May 12, 2022
NHS, Senior, Physician, International Society for Pharmacoeconomics and Outcomes Research, Health, International Society, Disease, VP, Platform, Degenerative disease, 2021 Essex County Council election, Patient, MA, Research, Efficiency, Medicine, Precision medicine, Patient experience, Specialty, Organization, HealthUnlocked, LLC, DC, Pharmaceutical industry, Inovalon, Insight

WALTHAM, Mass. and BOWIE, Md., May 12, 2022 /PRNewswire/ -- CorEvitas, LLC, the built-for-purpose provider of real-world evidence, and Inovalon, a leading provider of cloud-based platforms empowering data-driven healthcare, announce a joint educational symposium at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) annual meeting, being held in Washington, DC, from May 15-18, 2022.

Key Points: 
  • "Combining claims data with patient registry data presents the patient's lived experience, from medication adherence and hospital visits to pharmacy refills and socioeconomic factors."
  • However, these data are limited, typically only including patient demographics, diagnoses, procedures, and pharmacy script data.
  • By linking administrative claims data with clinical registry data, additional dimension is gained on both the patient journey and treatment experience.
  • The Precision Medicine business advances the molecular understanding of disease and prognostic tools by pairing registry data with select biospecimens and 'omics data.

Veradigm Presentations at ISPOR 2022 Highlight Broader Access to and Integration of Real-world Data Sources

Retrieved on: 
Wednesday, May 11, 2022
Software, General Health, Health, Data Management, Technology, Mobile, Wireless, Other Technology, Other Health, Real-World Evidence, EHR, American College of Cardiology, EDT, American College, YouTube, Twitter, Real, NASDAQ, COVID-19, Heart failure, SARS-COV-2, International Society for Pharmacoeconomics and Outcomes Research, Mining, Health, Cardiovascular disease, Infection, Research, Lorenzo patient record systems, Use, RWD, Patient, Electronic health record, Caregiver, Risk, Pharmacoeconomics, Diagnosis, Diabetes, Fatty liver disease, Practice Fusion, Connected, Technique, LinkedIn, NASH, RWE, Solution, Dashboard, Technology, Allscripts, MDRX, International Society, Multimedia, Pharmaceutical industry, Medical imaging, Perfume, Facebook

Key data presentations at ISPOR 2022 include:

Key Points: 
  • Key data presentations at ISPOR 2022 include:
    SARS-COV-2 Vaccine Breakthrough Infection Rates Based Data from 3 EHRS .
  • Comparing Fibrosis Staging Approaches Among Patients with Non-Alcoholic Steatohepatitis (NASH) Using Real World Data (RWD) .
  • Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale.
  • For more information on Veradigm, visit www.veradigm.com , or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube.

Nevro Announces Two Health Economic Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 Meeting

Retrieved on: 
Tuesday, November 30, 2021
Neurostimulation, RCT, International Society, HRU, Population, International Society for Pharmacoeconomics and Outcomes Research, Arm, Hospital, NYSE, PDN, Randomized controlled trial, Pharmacoeconomics, CMM, SCS, Chronic pain, Diabetic neuropathy, Hyperreflexia, Research, Poster, Length of stay, Hertz, Pharmaceutical industry, Medical imaging, Health insurance

REDWOOD CITY, Calif., Nov. 30, 2021 /PRNewswire/ --Nevro Corp.(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 virtual meeting.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 30, 2021 /PRNewswire/ --Nevro Corp.(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 virtual meeting.
  • ISPOR is a leading professional society for health economics and outcomes research.
  • "We also plan to submit additional findings from the 12-month analysis of the health economic data for publication by the end of this year.
  • The results showed a trend towards a reduction in hospitalization rates for 10 kHz SCS + CMM patients compared to patients treated with CMM alone.

Health Union to Present Research on Quality of Life Impact at Three Conferences Throughout Fall 2021

Retrieved on: 
Monday, October 25, 2021
Quality, Research, HS, Quality of life, Cystic fibrosis, Atrium Health Union, CFTR, Social Security, Family, Patient, International Society, Optimism, Report of the 1st Annual Symposium on Relaxed Improvisation, Conference, Cystic fibrosis transmembrane conductance regulator, Sex, Quality of Life Research, Multimedia, Hidradenitis suppurativa, Friends, Acquisition, Employment, International Society for Pharmacoeconomics and Outcomes Research, Medical device, Medicine, Health insurance

PHILADELPHIA, Oct. 25, 2021 /PRNewswire/ -- Health Union has been accepted to present research at three prestigious conferences throughout fall 2021, focusing on the experiences and perspectives of people living with cystic fibrosis, hidradenitis suppurativa and spondyloarthritis.

Key Points: 
  • PHILADELPHIA, Oct. 25, 2021 /PRNewswire/ -- Health Union has been accepted to present research at three prestigious conferences throughout fall 2021, focusing on the experiences and perspectives of people living with cystic fibrosis, hidradenitis suppurativa and spondyloarthritis.
  • The research, leveraging data from the company's syndicated, condition-specific In America surveys, highlights Health Union's deep understanding of the entire patient journey, including significant condition impact on quality of life.
  • Health Union will present quantitative research on how patients perceive the impact of cystic fibrosis transmembrane conductance regulator (CFTR) medication Trikafta on their futures and different aspects of quality of life.
  • Health Union is presenting research at the International Society for Quality of Life Research's 28th Annual Conference.